$AMRN we hit 23 well over a year ago. Since then every major American Medical association has endorsed VASCEPA. FDA ADCOM vote was 16-0. So much great news and stock is down. Why? Because of 50 million shares short keeping it down. (And the minor dilution which put 600 million on the bank). We still haven’t recovered from the announcement of ADCOM yet we cleared that hurdle with flying colors. That even assured a broader label. I know how this will end. And many shorts will be wiped out for life.
  • 21
  • 9